Abstract
CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind the CXCR7 receptor also, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors and outcome according to the expressions of CXCR4 and CXCR7 in renal cell carcinoma (RCC).
CXCR4 and CXCR7 expression were evaluated in 223 RCC patients through immunohistochemistry; moreover CXCR4 and CXCR7 were detected in 49 other consecutive RCC patients through RT- PCR.
CXCR4 expression was low in 42/223 RCC (18,8%), intermediate in 71/223 (31,9%) and high in 110/223 (49,3%). CXCR7 expression was low in 44/223 RCC patients (19,8%), intermediate in 65/223 (29,1%) and high in 114/223 (51,1%). High CXCR4 and high CXCR7 expression predicted shorter disease free survival. In multivariate analysis, high CXCR4 expression (p= 0.0061), high CXCR7 (p= 0.0194) expression and the concomitant high expression of CXCR4 and CXCR7 (p= 0.0235) are independent prognosis factors. Through RT-PCR, CXCR4 was overexpressed in 36/49 and CXCR7 in 33/49 samples correlating with symptoms at diagnosis and lymph nodes status. So we can hypothesize that CXCR4 and CXCR7, singularly evaluated and in combination, are valuable prognostic factors in RCC patients.
Keywords: CXCR4, CXCR7, disease free survival, molecular target, prognosis, renal cell carcinoma.
Current Cancer Drug Targets
Title:Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
Volume: 10 Issue: 7
Author(s): S. Perdona, S. Scala, G. Castello, S. Costantini, A. Ottaiano, L. Pucci, N. Longo, G. Carteni, G. Facchini, S. Pignata, C. D'Alterio, L. Claudio, L. Marra, R. Calemma, M. Cioffi, L. Portella, L. Cindolo, R. Franco, M. Polimeno and C. Consales
Affiliation:
Keywords: CXCR4, CXCR7, disease free survival, molecular target, prognosis, renal cell carcinoma.
Abstract: CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind the CXCR7 receptor also, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors and outcome according to the expressions of CXCR4 and CXCR7 in renal cell carcinoma (RCC).
CXCR4 and CXCR7 expression were evaluated in 223 RCC patients through immunohistochemistry; moreover CXCR4 and CXCR7 were detected in 49 other consecutive RCC patients through RT- PCR.
CXCR4 expression was low in 42/223 RCC (18,8%), intermediate in 71/223 (31,9%) and high in 110/223 (49,3%). CXCR7 expression was low in 44/223 RCC patients (19,8%), intermediate in 65/223 (29,1%) and high in 114/223 (51,1%). High CXCR4 and high CXCR7 expression predicted shorter disease free survival. In multivariate analysis, high CXCR4 expression (p= 0.0061), high CXCR7 (p= 0.0194) expression and the concomitant high expression of CXCR4 and CXCR7 (p= 0.0235) are independent prognosis factors. Through RT-PCR, CXCR4 was overexpressed in 36/49 and CXCR7 in 33/49 samples correlating with symptoms at diagnosis and lymph nodes status. So we can hypothesize that CXCR4 and CXCR7, singularly evaluated and in combination, are valuable prognostic factors in RCC patients.
Export Options
About this article
Cite this article as:
Perdona S., Scala S., Castello G., Costantini S., Ottaiano A., Pucci L., Longo N., Carteni G., Facchini G., Pignata S., D'Alterio C., Claudio L., Marra L., Calemma R., Cioffi M., Portella L., Cindolo L., Franco R., Polimeno M. and Consales C., Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer, Current Cancer Drug Targets 2010; 10 (7) . https://dx.doi.org/10.2174/156800910793605839
DOI https://dx.doi.org/10.2174/156800910793605839 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting <i>HIF1A</i> in <i>NONO-TFE3</i> Translocation Renal Cell Carcinoma
Current Cancer Drug Targets Carbonic Anhydrase Inhibitors and the Management of Cancer
Current Topics in Medicinal Chemistry Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design Efficacy Prediction of Jamu Formulations by PLS Modeling
Current Computer-Aided Drug Design Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus
Current Drug Targets From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry <i>Madhuca longifolia</i> Embedded Silver Nanoparticles Attenuate Diethylnitrosamine (DEN)-Induced Renal Cancer via Regulating Oxidative Stress
Current Drug Delivery Colloidal Microgels in Drug Delivery Applications
Current Pharmaceutical Design Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design